Thank you. A lot of people who invested in this issue don't have the temperament nor time horizon to stay the course. They lament, but should reexamine their original premise for investing/speculating in GNBT: Do diabetics want the product, does it work, will Oral-Lyn lead to greater compliance, will greater compliance bring down the cost of lifetime maintenance to the point where it makes economic sense for insurance companies to willingly pay for the device early on, since it is potentially a platform device will it become so ubiquitous that the public won't pay any attention to whether a person is taking a hit of insulin or any other drug administered in a similar manner?, etc. This stock has a history of drifting down then erupting on large volume. I love it when it is off the radar as it allows time to accumulate low price shares for those informed, willing to wait, and not faint of heart. I challenge anyone to show a single document indicating the device has any issues. The FDA apparently favors it too, witness the IND program.
News 
Market Data 
Discover 
AI
